bioRxivNeurosciencePreprint
Amyloid precursor protein mediates deficits in corticogenesis in Down syndrome cortical organoids
Karen Rakowiecki, Deepika PateliD, Luis Aponte Cofresi, Orly LazaroviD
Abstract
Down syndrome (DS), due to trisomy 21 (T21), occurs in approximately 14.14 per 10,000 live births in the United States. Reduced neural progenitor cell (NPC) proliferation, delayed neurogenesis, impaired cortical lamination and altered cell fate specification are thought to contribute to cognitive impairments in DS individuals. The molecular mechanisms underlying these deficits are not fully understood. Notably, Amyloid precursor protein (APP), located on human chromosome 21 (HSA21), has been extensively implicated in these processes. Mouse models only partially recapitulate DS phenotypes due to genetic, developmental, and species-specific differences. Recent advances in induced pluripotent stem cell (iPSC) derived 3D cortical organoids allow for the study of DS cortical development in a human model system. Here, we show that normalizing APP gene copy number in DS cortical organoids ameliorated deficits in NPC proliferation, neuronal differentiation, and transcriptional programs. Our results demonstrate the value of cortical organoids in uncovering gene-specific roles in DS pathogenesis and identify APP as a promising target for addressing early neurodevelopmental impairments.
- organism: human
- assay: spatial transcriptomics
- research focus: cell type annotation
- research focus: clustering
- research focus: differential expression
- research focus: gene regulatory network inference
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Amyloid precursor protein dosage normalization rescues neurogenesis and Alzheimer's Disease phenotypes associated with Down Syndrome
Deepika Patel, Karen Rakowiecki, Orly Lazarov·Medical Research ArchivesPeer-reviewed·Jan 1, 2026
- Trisomy 21 cerebral organoids exhibit Alzheimer's disease amyloid and apolipoprotein E co-pathologies
Breanna R. Dooling, Anne Vielle, … Noah R. Johnson·bioRxiv·Jul 7, 2026
- APP Dosage and Extracellular Domain Variants Drive Distinct Defects in Neurogenesis modeled in Down Syndrome iPS cells
Melvys Valledor, Kelly Smith, … Lucas Javier Sosa·bioRxiv·Aug 6, 2026
- Genetic mapping of APP and amyloid-β biology modulation by trisomy 21
Paige Mumford, Justin Tosh, … Frances K. Wiseman·Journal of NeurosciencePeer-reviewed·Jul 14, 2022
- Extracellular matrix defects destabilise apical cytoarchitecture and mechanical properties during early Down syndrome neurodevelopment
Teresa P. Silva, Ekaterina R. Iijima, … Paula Alexandre·bioRxiv·Jun 23, 2026
- Endosomal structure and APP biology are not altered in preclinical cellular models of Down syndrome
Claudia Cannavo, Karen Cleverley, … Frances K. Wiseman·bioRxiv·Dec 30, 2021